Development of an integrated prostate cancer research information system.
about
Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancerEvaluation of 8q24 and 17q risk loci and prostate cancer mortality.Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer.Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer.SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancerFunctional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits.Genome-wide association study of prostate cancer mortalityInherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy.Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.Functional enhancers at the gene-poor 8q24 cancer-linked locus.PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6.Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness.Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort.Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.Suicidal ideation in prostate cancer survivors: understanding the role of physical and psychological health outcomes.Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.Identifying suicidal symptoms in prostate cancer survivors using brief self-report.Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy.Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer.
P2860
Q24657886-7FC5C70B-F706-497D-9054-D83D38FB44F5Q30494721-CF03EF38-D591-41F3-92D2-A4B529A8D5CAQ33667666-61B10D1F-F5AB-46EB-9B07-53164954DA2CQ34268286-3AC43784-FE4D-461D-A833-384105091110Q34440647-6BAE6D52-A5C7-4FEE-B8DA-3C9FCC7F492DQ35112055-6F617D9A-E8F6-4A76-B7A8-7D72BA1DF6BCQ35206829-8265E314-71F2-4CDA-8928-742F9D61495BQ35399770-6682151C-F511-44CD-BDFF-FD497C5594B0Q37127302-06A0969E-86DD-44EF-820E-E0A0358A2CC9Q37262639-4E4A4B9A-8405-497C-9764-7F5A71F334DBQ37279616-CBBEFCCE-E7CF-48B6-ABDE-A4B1FDDB8D01Q38246587-1080BA8A-E529-4375-873B-CAC9225EDFD6Q38728375-06A04C10-D369-436A-9750-64F9E67319F0Q38852322-660BF23C-14A4-4372-80E7-AE9BAC7EE029Q40395168-5FBD4041-1699-4438-BA45-CBD750131C93Q42019892-56F840A0-1ADE-48A8-9B93-6E896E6FF348Q42035769-95C4E3DE-B1C7-40C9-8FEC-561F4EC04113Q42093452-F6EE14CE-6F4B-4AD7-A490-784983BAC5DCQ42700287-E444FF41-C4BF-4B61-B5AA-6B543BEBD452Q43045850-F2BB6E72-4E35-4E48-9606-43DFEE9A7738Q45898491-26F099DF-902C-4084-A04F-BDB522B11D9FQ47239084-6DFD6EA6-0364-4839-B127-42CB157090F8Q47347786-778263C9-F6DA-44F7-8555-371D21667CD8Q48230781-855A26E7-35D9-4CF0-9778-39D0F8333F10Q50951455-B791D331-9F85-4549-9CFA-E9484681B776Q53261068-7F71FC7F-FBE2-45A9-8DD9-4B71F137814EQ55441916-7FAEDD11-0B40-4461-8BE5-E05D0DA55CA9
P2860
Development of an integrated prostate cancer research information system.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Development of an integrated prostate cancer research information system.
@ast
Development of an integrated prostate cancer research information system.
@en
Development of an integrated prostate cancer research information system.
@nl
type
label
Development of an integrated prostate cancer research information system.
@ast
Development of an integrated prostate cancer research information system.
@en
Development of an integrated prostate cancer research information system.
@nl
prefLabel
Development of an integrated prostate cancer research information system.
@ast
Development of an integrated prostate cancer research information system.
@en
Development of an integrated prostate cancer research information system.
@nl
P2093
P50
P356
P1476
Development of an integrated prostate cancer research information system
@en
P2093
Arthur Nevins
Beth Katcher
Carolyn Evan
Daniel J George
Helen Waldron
James Talcott
Jane Weeks
Jerome P Richie
John Orechia
P356
10.3816/CGC.2006.N.019
P407
P577
2006-06-01T00:00:00Z